Given that the added risk is likely to be modest and the prevalence of prostate cancer is high, a literature review estimated a 2.13-fold (95% CI, 1.45–2.80) increased risk of prostate cancer for male carriers in clinic-based retrospective cohorts, and 2.28 (95% CI, 1.37–3.19) for all men from mutation-carrying families.60 Lynch syndrome male family members should also be considered for earlier and more frequent screening.61 The currently ongoing IMPACT trial aims to assess the use of PSA-based screening in BRCA1 and BRCA2 carrier Lynch syndrome patients (MSH1, MSH2, and MLH1). The gene discussed is BRCA2; the disease is Familial prostate cancer.